Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 22 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact22 DOIs

Deposit reference lists for 2 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact2 DOIs

DOIs for this ISSN

Showing the top 5 of 187 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Oxidative Stress and ROS Link Diabetes and Cancer (10.3390/jmp5010007)	ORCID	38.60	34
2	The Papanicolaou Society of Cytopathology System for Reporti… (10.3390/jmp2020010)	ORCID	25.00	9
3	The Potential Role of Histone Modifications in Glioblastoma… (10.3390/jmp4040018)	ORCID	25.00	9
4	The Roles of Calcium Ions in Parkinson’s Disease: Calcium Ch… (10.3390/jmp3040021)	ORCID	23.86	8
5	Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibi… (10.3390/jmp6040025)	ORCID	21.13	6
6	The Milan System, from Its Introduction to Its Current Adopt… (10.3390/jmp2020012)	ORCID	19.45	5
7	The Value of Fine Needle Aspiration Biopsy in the Pre-Operat… (10.3390/jmp3040020)	ORCID	15.05	3
8	RNA-Based Next-Generation Sequencing in the Somatic Molecula… (10.3390/jmp3040026)	ORCID	15.05	3
9	Metastatic Breast Cancer: Cytology Diagnosis with Implicatio… (10.3390/jmp4010001)	ORCID	15.05	3
10	Molecular Pathogenesis of Renal Neoplasms in Patients with B… (10.3390/jmp5040032)	ORCID	15.05	3
11	An Independent Assessment of a Commercial Clinical Interpret… (10.3390/jmp3030012)	ORCID	11.93	2
12	Regulation of a Metabolic Gene Signature in Response to Resp… (10.3390/jmp5010009)	ORCID	11.93	2
13	Precision Prevention: The 2019 ASCCP Risk-Based Management C… (10.3390/jmp2030023)	ORCID	7.53	1
14	The Relationship between Mutations in Gene-Specific Domains… (10.3390/jmp3030015)	ORCID	7.53	1
15	MET Exon 14 Variants in Non-Small Cell Lung Carcinoma: Preva… (10.3390/jmp4010006)	ORCID	7.53	1
16	Activating Transcription Factor 1 (ATF1) Immunohistochemical… (10.3390/jmp4030016)	ORCID	7.53	1
17	A Novel Single-Tube Next Generation Sequencing Assay for B-C… (10.3390/jmp5010004)	ORCID	7.53	1
18	The Birth of the Journal of Molecular Pathology (10.3390/jmp1010001)	ORCID	0.00	0
19	Are Microsatellite Patterns Specific for Tumor Types? A Pilo… (10.3390/jmp1010002)		0.00	0
20	Comparison of the Hybrid Capture II Method with a PCR-Based… (10.3390/jmp1010003)		0.00	3
21	ROC Analysis Identifies Baseline and Dynamic NLR and dNLR Cu… (10.3390/jmp1010004)		0.00	3
22	Persistent Ependymal Tumor Arising from an Immature Ovarian… (10.3390/jmp1010005)		0.00	0
23	Concomitant Rare KRAS and BRAF Mutations in Lung Adenocarcin… (10.3390/jmp1010006)		0.00	3
24	A Comparison Between First-, Second- and Third-Generation Ep… (10.3390/jmp2010001)		0.00	11
25	Practical Applications of Molecular Testing in the Cytologic… (10.3390/jmp2010002)		0.00	5
26	Collection and Handling of Thoracic Small Biopsy and Cytolog… (10.3390/jmp2010003)		0.00	0
27	Different Methods in HPV Genotyping of Anogenital and Oropha… (10.3390/jmp2010004)		0.00	2
28	PIK3CA Mutation Assessment in HR+/HER2− Metastatic Breast Ca… (10.3390/jmp2010005)		0.00	12
29	Challenges of ICC and FISH in the Field of Targeted Therapie… (10.3390/jmp2020006)		0.00	3
30	The International System for Reporting Serous Fluid Cytopath… (10.3390/jmp2020007)		0.00	12
31	Thyroid and Molecular Testing. Advances in Thyroid Molecular… (10.3390/jmp2020008)		0.00	10
32	Mismatch Repair Status Characterization in Oncologic Patholo… (10.3390/jmp2020009)		0.00	12
33	Cytopathology Practice in the COVID-19 Era: Focus on Sample… (10.3390/jmp2020011)		0.00	4
34	Analysis of Copy Number Variations in Solid Tumors Using a N… (10.3390/jmp2020013)		0.00	8
35	Molecular Tests for Risk-Stratifying Cytologically Indetermi… (10.3390/jmp2020014)		0.00	15
36	What Is New in Biomarker Testing at Diagnosis of Advanced No… (10.3390/jmp2020015)		0.00	11
37	Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic… (10.3390/jmp2020016)		0.00	22
38	Emerging Biomarkers for the Selection of Advanced NSCLC-Affe… (10.3390/jmp2020017)		0.00	2
39	Modern Challenges for Early-Phase Clinical Trial Design and… (10.3390/jmp2030018)		0.00	4
40	Prognostic Significance of JMJD3 Expression in Pleural Mesot… (10.3390/jmp2030019)		0.00	0
41	Molecular Testing of Thyroid Fine-Needle Aspiration: Local I… (10.3390/jmp2030020)		0.00	5
42	Liquid Biopsy Analysis in Clinical Practice: Focus on Lung C… (10.3390/jmp2030021)		0.00	10
43	Liquid Biopsy for Biomarker Testing in Non-Small Cell Lung C… (10.3390/jmp2030022)		0.00	34
44	Clinical and Molecular Features of Anti-CENP-B Autoantibodie… (10.3390/jmp2040024)		0.00	12
45	Conventional Transbronchial Needle Aspiration (cTBNA) and EB… (10.3390/jmp2040025)		0.00	4
46	Progression of Well-Differentiated Papillary Mesothelial Tum… (10.3390/jmp2040026)		0.00	1
47	From Information Overload to Actionable Insights: Digital So… (10.3390/jmp2040027)		0.00	6
48	Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Mo… (10.3390/jmp2040028)		0.00	0
49	The Multifaceted Profile of Thyroid Disease in the Backgroun… (10.3390/jmp3010001)		0.00	4
50	Tissue Microarray from Cell Block Material (cbTMA)—An Additi… (10.3390/jmp3010002)		0.00	2